CLGN
Price:
$3.725
Market Cap:
$42.67M
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair m...[Read more]
Industry
Biotechnology
IPO Date
2018-01-31
Stock Exchange
NASDAQ
Ticker
CLGN
According to CollPlant Biotechnologies Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -2.43. This represents a change of -33.12% compared to the average of -3.63 of the last 4 quarters.
The mean historical PE Ratio of CollPlant Biotechnologies Ltd. over the last ten years is 35.13. The current -2.43 PE Ratio has changed -791.79% with respect to the historical average. Over the past ten years (40 quarters), CLGN's PE Ratio was at its highest in in the September 2020 quarter at 20.65. The PE Ratio was at its lowest in in the June 2021 quarter at -17.81.
Average
35.13
Median
-3.57
Minimum
-12.77
Maximum
398.76
Discovering the peaks and valleys of CollPlant Biotechnologies Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 560.37%
Maximum Annual PE Ratio = 398.76
Minimum Annual Increase = -3222.44%
Minimum Annual PE Ratio = -12.77
Year | PE Ratio | Change |
---|---|---|
2023 | -10.37 | 88.55% |
2022 | -5.50 | -101.38% |
2021 | 398.76 | -3222.44% |
2020 | -12.77 | 560.37% |
2019 | -1.93 | -34.38% |
2018 | -2.95 | -25.62% |
2017 | -3.96 | 58.36% |
2016 | -2.50 | -21.43% |
2015 | -3.18 | -26.48% |
2014 | -4.33 | 119.36% |
The current PE Ratio of CollPlant Biotechnologies Ltd. (CLGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
127.63
5-year avg
73.64
10-year avg
35.13
CollPlant Biotechnologies Ltd.’s PE Ratio is greater than Keros Therapeutics, Inc. (-12.95), greater than Merus N.V. (-14.37), less than Vericel Corporation (2.74K), less than Century Therapeutics, Inc. (-0.79), less than Shattuck Labs, Inc. (-0.68), greater than C4 Therapeutics, Inc. (-4.29), less than Eliem Therapeutics, Inc. (-2.42), less than Prelude Therapeutics Incorporated (-0.71), greater than Monte Rosa Therapeutics, Inc. (-4.86), greater than Molecular Partners AG (-3.01), greater than MediciNova, Inc. (-10.09), greater than Anebulo Pharmaceuticals, Inc. (-5.95), greater than Champions Oncology, Inc. (-16.97), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Replimune Group, Inc. (-3.79), greater than Crinetics Pharmaceuticals, Inc. (-17.41), greater than NewAmsterdam Pharma Company N.V. (-7.35), greater than PureTech Health plc (-54.81), less than Ikena Oncology, Inc. (-1.24), less than Enochian Biosciences, Inc. (-1.35), less than HCW Biologics Inc. (-0.42), greater than Exicure, Inc. (-3.13),
Company | PE Ratio | Market cap |
---|---|---|
-12.95 | $2.26B | |
-14.37 | $3.53B | |
2.74K | $2.18B | |
-0.79 | $107.59M | |
-0.68 | $54.89M | |
-4.29 | $458.83M | |
-2.42 | $342.68M | |
-0.71 | $67.13M | |
-4.86 | $545.60M | |
-3.01 | $247.30M | |
-10.09 | $82.40M | |
-5.95 | $49.01M | |
-16.97 | $57.64M | |
-3.52 | $108.71M | |
-3.79 | $824.30M | |
-17.41 | $5.13B | |
-7.35 | $1.61B | |
-54.81 | $498.68M | |
-1.24 | $82.52M | |
-1.35 | $45.38M | |
-0.42 | $16.26M | |
-3.13 | $5.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CollPlant Biotechnologies Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CollPlant Biotechnologies Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CollPlant Biotechnologies Ltd.'s PE Ratio?
How is the PE Ratio calculated for CollPlant Biotechnologies Ltd. (CLGN)?
What is the highest PE Ratio for CollPlant Biotechnologies Ltd. (CLGN)?
What is the 3-year average PE Ratio for CollPlant Biotechnologies Ltd. (CLGN)?
What is the 5-year average PE Ratio for CollPlant Biotechnologies Ltd. (CLGN)?
How does the current PE Ratio for CollPlant Biotechnologies Ltd. (CLGN) compare to its historical average?